TabLe 3.

Risk of cardia and noncardia gastric adenocarcinoma according to genotype

Polymorphism	Noncardia (n=78)		Cardia (n=27)
	n (%)	OR (95% CI); P	n (%)	OR (95% CI); P
IL-1β −511C→T
CC	39 (50.0)	Reference	13 (48.2)	Reference
CT	30 (38.5)	0.83 (0.48–1.43); 0.6	12 (44.4)	0.99 (0.43–2.28); 0.9
TT	9 (11.5)	0.84 (0.28–1.94); 0.7	2 (7.4)	0.66 (0.12–2.64); 0.5
IL-4R −3223C→T
CC	36 (46.2)	Reference	17 (63.0)	Reference
CT	32 (41.0)	1.51 (0.87–2.60); 0.2	8 (29.6)	0.80 (0.33–1.93); 0.66
TT	10 (12.8)	3.08 (1.25–7.58); 0.023	2 (7.4)	1.30 (0.27–6.27); 0.8
IL-8 −251T→A
TT	25 (32.1)	Reference	6 (22.2)	Reference
TA	38 (48.7)	1.11 (0.62–1.98); 0.7	16 (59.3)	1.95 (0.73–5.20); 0.2
AA	15 (19.2)	1.02 (0.49–2.13); 0.9	5 (18.5)	1.42 (0.41–4.91); 0.63
IL-10 −1082 A→G
AA	34 (43.6)	Reference	9 (33.3)	Reference
AG	36 (46.1)	0.80 (0.46–1.38); 0.47	13 (48.2)	1.09 (0.45–2.66); 0.9
GG	8 (10.3)	1.79 (0.25–1.42); 0.28	5 (18.5)	1.41 (0.44–4.51); 0.6
TNF-α −308 G→A
GG	57 (73.1)	Reference	21 (77.8)	Reference
GA	20 (25.6)	1.56 (0.85–2.86); 0.2	6 (22.2)	1.27 (0.48–3.34); 0.72
AA	1 (1.3)	1.72 (0.15–19.3); 0.7	0 (0)	–

IL Interleukin; TNF Tumour necrosis factor